Accordingly, gallium compounds, which are already in several phase II trials (45, 46), might be considered as an addition to the current regimens for treatment of BL and other cancers, where nuclear NFATc1 expression is evident. The gene discussed is NFATC1; the disease is Burkitt lymphoma.